Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9397905 | 0.67 | TSHR (0.35) | TSHR | |
| SCHEMBL12687548 | 0.63 | — | — | |
| SCHEMBL20134669 | 0.63 | — | — | |
| SCHEMBL26220594 | 0.63 | — | — | |
| SCHEMBL8611 | 0.62 | — | — | |
| SCHEMBL43449 | 0.61 | — | — | |
| SCHEMBL130968 | 0.61 | — | — | |
| SCHEMBL10358289 | 0.61 | — | — | |
| SCHEMBL16499934 | 0.61 | — | — | |
| SCHEMBL25438483 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-7794917-B2 | Curable composition, color filter and manufacturing method thereof | FUJIFILM CORPORATION (JP) | 2010-09-14 | — | — | US | disclosed |
| EP-1308540-B1 | Plating bath and method for depositing a metal layer on a substrate | SHIPLEY CO LLC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20080076043-A1 | CURABLE COMPOSITION, COLOR FILTER AND MANUFACTURING METHOD THEREOF | FUJIFILM CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1903393-A2 | Curable composition, color filter and manufacturing method thereof | FUJIFILM Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-1543983-B1 | Ink-jet recording medium and process for producing the same | FUJIFILM CORP (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | disclosed |
| US-6736954-B2 | A METAL PLATING BATH COMPRISING METAL SALTS AND AN ADDITIVE CONSUMPTION INHIBITOR(A HETEROATOM ORGANIC COMPOUNDS WHICH MAY CONTAIN SULFUR, OXYGEN OR NITROGEN HETEROATOMS) IMPROVE THE BRIGHTNESS OF PLATED METAL AS WELL AS THE DUCTILITY | SHIPLEY COMPANY, L.L.C. | 2004-05-18 | — | — | US | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1308540-A1 | Plating bath and method for depositing a metal layer on a substrate | Shipley Co. L.L.C. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-5563292-A | TREATING HYPERPROLIFERATIVE SKIN DISEASE | SCHERING CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5318971-A | Also antihyperproliferative skin disease agents, e.g. psoriaisis; side effect reduction | SCHERING CORPORATION (US) | 1994-06-07 | — | — | US | disclosed |
| US-5064837-A | Antiallergens | SCHERING CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | TSHR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.